Results 271 to 280 of about 1,297,457 (342)

Engaging natural regulatory myeloid cells to restrict T-cell hyperactivation-induced liver inflammation via extracellular vesicle-mediated purine metabolism regulation. [PDF]

Theranostics
Yang F, Men R, Lv L, Zhou L, Deng Q, Wang X, Liu J, Yang L.   +7 more
europepmc   +1 more source

Phytosphingosine Alleviates Cigarette Smoke‐Induced Bronchial Epithelial Cell Senescence in Chronic Obstructive Pulmonary Disease by Targeting the Free Fatty Acid Receptor 4

MedComm, Volume 6, Issue 9, September 2025.
ABSTRACT Chronic obstructive pulmonary disease (COPD) is a complex and irreversible respiratory disorder with a poor prognosis and a lack of effective pharmaceutical treatment. Our previous metabolomics study identified phytosphingosine (PHS) as a key differential metabolite in COPD that is positively correlated with lung function.
Yuan Zhan, Zhesong Deng, Ruonan Yang, Shanshan Chen, Jiaheng Zhang, Yating Zhang, Hao Fu, Qian Huang, Yiya Gu, Zhilin Zeng, Jinkun Chen, Jixian Zhang, Jixing Wu, Jungang Xie   +13 more
wiley   +1 more source

Staphylococcus aureus mutants resistant to the feed-additive monensin show increased virulence and altered purine metabolism. [PDF]

mBio
Warsi OM, Upterworth LM, Breidenstein A, Lustig U, Mikkelsen K, Nagy T, Szatmari D, Ingmer H, Andersson DI.   +8 more
europepmc   +1 more source

Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss

MedComm, Volume 6, Issue 9, September 2025.
In this study, we found the close proximity of NUDT15 and RB1 in terms of chromosome location and exploited the fact that NUDT15 deficiency induces 6MP‐related adverse drug reactions, thus providing a possible collateral lethality (a specific type of synthetic lethality) strategy to treat RB1‐deficient tumors (created with www.biorender.com).
Tao Zhou, Huayun Yan, Dandan Yin, Yun Deng, Huancheng Fu, Zichen Zhao, Shuang Li, Xiaoxi Lu, Yiqi Deng, Hai‐Ning Chen, Wei‐Han Zhang, Yunying Shi, Yangjuan Bai, Bei Cai, Lanlan Wang, Zhaoqian Liu, Wei Zhang, Lili Jiang, Yang Shu, Bo Liu, Yan Zhang, Heng Xu   +21 more
wiley   +1 more source

Primary Progressive Multiple Sclerosis: New Therapeutic Approaches

Neuropsychopharmacology Reports, Volume 45, Issue 3, September 2025.
Primary progressive MS affects 10%–15% of MS patients, causing irreversible neurological impairment. Drugs like ocrelizumab show promise, while high‐dose biotin, simvastatin, and coenzyme Q10 are under investigation. Gene therapy and stem cell treatments also show potential.
Morteza Rajabi, Sajjad Shafaeibajestan, Sevda Asadpour, Ghazal Alyari, Niloofar Taei, Moein Kohkalani, Ramin Raoufinia, Hamed Afarande, Ehsan Saburi   +8 more
wiley   +1 more source

Ethanol Extracts from Torreya grandis Seed Have Potential to Reduce Hyperuricemia in Mouse Models by Influencing Purine Metabolism. [PDF]

Foods
Yao J, Bai E, Duan Y, Huang Y.
europepmc   +1 more source

Bioinformatic validation and machine learning-based exploration of purine metabolism-related gene signatures in the context of immunotherapeutic strategies for nonspecific orbital inflammation. [PDF]

Front Immunol
Wu Z, Fang C, Hu Y, Peng X, Zhang Z, Yao X, Peng Q.   +6 more
europepmc   +1 more source